ArticleHaematologica2026

Brentuximab vedotin plus nivolumab as bridging therapy to CAR T-cells in relapsed/refractory primary mediastinal B-cell lymphoma.

Armando Santoro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.